Cardiac Pacemakers Global Market Report 2024

The cardiac pacemaker is defined by small electronic devices that generate electrical impulses to regulate heartbeats and treat conditions like arrhythmias. These devices play a crucial role in preventing the heart from beating too fast or too slow.

The primary categories of cardiac pacemakers consist of implantable and external variants. Implantable cardiac pacemakers, installed through surgery, are electronic devices generating electrical impulses within the chest to maintain a regular heart rate. Different technologies in cardiac pacemakers encompass biventricular, single-chambered, and dual-chambered systems. These devices find applications in treating various conditions such as arrhythmias, heart blockage, atrial fibrillation, long QT syndrome, and congestive cardiac failure. Cardiac pacemakers serve end-users including clinics, hospitals, ambulatory surgical centers, and cardiac care centers. The market continues to evolve with ongoing advancements in technology and surgical procedures, contributing to improved patient care and outcomes.

The cardiac pacemakers market research report is one of a series of new reports that provides cardiac pacemakers market statistics, including cardiac pacemakers industry global market size, regional shares, competitors with a cardiac pacemakers market share, detailed cardiac pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac pacemakers industry. This cardiac pacemakers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac pacemakers market size has grown strongly in recent years. It will grow from $4.58 billion in 2023 to $4.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth witnessed in the historic period in the cardiac pacemaker market is influenced by several factors. These include the aging population and the increased prevalence of cardiovascular diseases, a rising awareness of arrhythmias and the necessity for effective treatment, investments in research and development to drive pacemaker innovation, the evolution of healthcare infrastructure, and improved access to medical devices. Additionally, regulatory approvals for novel pacemaker features and technologies have played a significant role in shaping the historical growth trajectory of this market.

The cardiac pacemakers market size is expected to see strong growth in the next few years. It will grow to $6.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The forecasted growth in the cardiac pacemaker market is driven by various factors. Notable among these are an increased focus on lead durability and the reduction of complications associated with pacemakers, the implementation of remote programming and telehealth services to cater to pacemaker patients, the expansion of emerging markets coupled with a rise in healthcare expenditure, advancements in battery technologies to extend pacemaker lifespans, and regulatory support for expediting pacemaker approvals. Furthermore, significant trends anticipated in the forecast period include advancements in electrophysiology for precision implantation, the integration of pacemaker data into electronic health records (EHRs), the incorporation of artificial intelligence (AI) for predictive pacemaker maintenance, ongoing advancements in pacemaker technology such as miniaturization, and the increasing adoption of telemedicine and remote monitoring.

The surge in cardiovascular diseases is a significant driver for the cardiac pacemaker market. Cardiovascular diseases encompass a range of disorders affecting the heart or blood vessels, including arrhythmias, aorta disease, congenital heart disease, and heart attacks. To address the growing global health concern, cardiac pacemakers, which generate electric activity, are employed in treating patients with cardiovascular diseases. In September 2023, the World Health Organization reported that annually, 41 million deaths, accounting for 74% of non-communicable diseases, were attributed to cardiovascular diseases, highlighting the pressing need for advancements in cardiac care. Consequently, the increasing prevalence of cardiovascular diseases is expected to propel the growth of the cardiac pacemaker market.

Government initiatives aimed at fostering research and development in healthcare are poised to drive the cardiac pacemaker market. These initiatives, undertaken by government authorities at various levels, encompass actions, programs, and policies designed to address healthcare challenges and promote positive societal changes. Notably, in 2022, the UK government allocated £260 million ($270.65 million) in funding to bolster healthcare research and manufacturing. This commitment, from the Department of Health and Social Care, supports NHS-led health research into diagnostics and treatments, with a focus on enhancing clinical research services. Additionally, £60 million ($63.60 million) was earmarked to expand life sciences manufacturing in the UK. Such government initiatives play a pivotal role in advancing cardiac care and fueling the growth of the cardiac pacemaker market.

Innovations, particularly the development of leadless cardiac pacemakers, emerge as a key trend in the cardiac pacemaker market. Major players in the industry are actively introducing innovative solutions to enhance patient care and market competitiveness. The leadless pacemaker, a self-contained generator and electrode system, offers significant advantages, being 90% smaller than traditional transvenous pacemakers. Its implantation via a femoral vein transcatheter technique eliminates the need for chest incisions and subcutaneous generator pockets. Notably, in January 2022, Medtronic PLC, an Ireland-based medical devices company, introduced the Micra AV Transcatheter Pacing System (TPS), a leadless pacemaker designed for patients with compromised electrical communication between the heart's ventricle and atria, addressing a critical aspect of cardiac health with cutting-edge technology.

Leading companies in the cardiac pacemaker market are driving revenue growth through the development of innovative products, exemplified by the introduction of the Micra AV (CNT) series, the world's smallest pacemaker. Launched by Medtronic in June 2021, this miniaturized, fully self-contained pacemaker utilizes advanced pacing technology to address atrioventricular (AV) block patients through a minimally invasive approach. Notably, the Micra AV pacemaker is groundbreaking, as it can sense atrial activity without the need for a lead or device in the upper chamber of the heart. This innovative technology allows the pacemaker to synchronize the ventricles, enhancing heart efficiency and reducing the risk of heart failure.

In July 2022, Orchestra BioMed, a US-based company specializing in transformative therapeutic products, entered into a collaboration with Medtronic. The partnership between Medtronic and Orchestra BioMed aims to develop BackBeat Cardiac Neuromodulation Therapy (CNT), a potential therapeutic solution for hypertension in individuals requiring a cardiac pacemaker. This collaboration underscores the commitment of major players, such as Medtronic, to pioneer advancements in healthcare technology and contribute to the evolution of cardiac care.

Major companies operating in the cardiac pacemakers market include Medtronic PLC, Lepu Medical Technology Co., Abbott Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, Oscor Inc., Osypca Medical GmbH, Zoll Medical Corporation, MicroPort Scientific Corporation, Cook Group Incorporated, Sorin Group, Vitatron & Medical Co., Cordis Inc., Shree Pacetronix Limited, Medico SpA, St. Jude Medical, LivaNova PLC, Schiller AG, BTL Industries Inc., CCC Medical Devices, Cardiostim, Advena Ltd., Mediana Co. Ltd., Vimecon GmbH, Cardiac Science Corporation, Greatbatch Medical, Galix Biomedical Instrumentation, Nanjing MicroPort Medical, A&E Medical Corporation, Cardionovum GmbH

North America was the largest region in the cardiac pacemakers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac pacemakers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cardiac pacemakers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The cardiac pacemaker market consists of sales of single chamber, dual chamber and Biventricular pacemakers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.